Disclosure Quest - Search SEC Filings

Name	Type of Offering	Accepted Date
CuraSen Therapeutics, Inc. See All Filings	D	2024-09-18 16:56:47 UTC
Amount To Be Raised $45,690,305 Associated Brokers / Dealers N/A CIK Number 0001765883 Filed Document 0001765883-24-000002 Exclusions or Exemptions 506b Accepted Date 2024-09-18 16:56:47 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
CuraSen Therapeutics, Inc. See All Filings	D/A	2023-10-12 15:49:48 UTC
Amount To Be Raised $20,814,709 Associated Brokers / Dealers N/A CIK Number 0001765883 Filed Document 0001567619-23-007439 Exclusions or Exemptions 506b Accepted Date 2023-10-12 15:49:48 UTC Type of Offering D/A Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
CuraSen Therapeutics, Inc. See All Filings	D	2022-11-10 13:14:24 UTC
Amount To Be Raised $14,999,997 Associated Brokers / Dealers N/A CIK Number 0001765883 Filed Document 0001567619-22-019469 Exclusions or Exemptions 506b Accepted Date 2022-11-10 13:14:24 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
CuraSen Therapeutics, Inc. See All Filings	D	2021-11-05 17:02:42 UTC
Amount To Be Raised $18,000,000 Associated Brokers / Dealers N/A CIK Number 0001765883 Filed Document 0001567619-21-019414 Exclusions or Exemptions 506b Accepted Date 2021-11-05 17:02:42 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity
CuraSen Therapeutics, Inc. See All Filings	D	2019-01-24 20:04:16 UTC
Amount To Be Raised $54,499,989 Associated Brokers / Dealers N/A CIK Number 0001765883 Filed Document 0001765883-19-000001 Exclusions or Exemptions 506c Accepted Date 2019-01-24 20:04:16 UTC Type of Offering D Industry Biotechnology Principal Place of Business CALIFORNIA Revenue or Assets Decline to Disclose Type of Security Equity